Board Meeting outcome for standalone and consolidated unaudited financial results for the second quarter and half-year ended 30 September 2025; with issuance and allotment of 1770710 equity ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sampre Nutritions' board, meeting on 5 November 2025, approved standalone and consolidated unaudited results for Q2 and H1 FY26 (ended 30 September 2025). Standalone revenue from operations rose to INR 999.74 lakhs in Q2 FY26 from INR 726.88 lakhs in Q2 FY25, with H1 revenue climbing to INR 2,086.39 lakhs from INR 1,178.09 lakhs (about 77% growth). Standalone profit after tax jumped to INR 89.47 lakhs in Q2 (vs INR 12.45 lakhs) and INR 160.41 lakhs for H1 (vs INR 37.09 lakhs), marking a sharp turnaround from the FY25 full-year loss of INR 730.92 lakhs. The board also approved the preferential allotment of 17,70,710 equity shares (face value INR 5, issue price INR 42) to promoters Brahma Gurbani and Meera Gurbani by converting unsecured loans worth about INR 7.44 crore, and cleared the draft EGM notice for shareholder approval. The auditor (N G Rao & Associates) issued an unqualified limited review on both standalone and consolidated results.
Strong top-line growth and a clear turnaround to profit are positive for shareholders, though the promoter loan-to-equity conversion will dilute existing public shareholders slightly and adds to equity capital. Operating cash flow turned healthy at INR 326.27 lakhs for H1, but heavy investing outflows (INR 753 lakhs into subsidiaries) and rising long-term borrowings warrant a watch on capital allocation.